|
|
|
| Research progress on drug-resistance of Elizabethkingia meningoseptica |
| WU Qile1, FANG Zixuan1, YUAN Shuying1, CHEN Yanwen1, CHEN Li2, SUN Guiqin1 |
| 1. School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China; 2. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China |
|
|
|
|
Abstract Elizabethkingia meningosepticum (EM), which causes nosocomial pneumonia, neonatal meningitis, bacteremia and other diseases, is one of the most important pathogens of nosocomial infections. In recent years, the detection rate of EM in the intensive care unit (ICU) has shown an upward trend. Due to the widespread use of antibiotics, EM is multi-drug resistant to commonly used clinical antibiotics such as β-lactams, aminoglycosides and fluoroquinolone, which brings great difficulties to clinical treatment. At present, researches on EM resistance mechanisms in different countries mainly include the production of drug-inactivating enzymes, changes in drug targets, and the formation of biofilms. EM has multiple drug-resistant genes such as GOB, BLaB, CME, which mediate their multiple resistance. This article reviewed the drug resistance and resistance mechanism of EM, hoped to provide references for the prevention and control of nosocomial infections of EM.
|
|
Received: 15 January 2021
Published: 25 February 2022
|
|
|
|
Corresponding Authors:
SUN Guiqin，CHEN Li
|
|
|
|
|
|
|
2022, Vol. 17 
